

ACCoRd: A phase III study to determine the role of ixazomib as an **Augmented Conditioning** therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT **Consolidation** and maintenance strategy in patients with **Relapsed** multiple myeloma (UK-MRA Myeloma XII)

Please speak to your GP, clinician, or clinical nurse specialist if you feel affected by the reporting of these results. Additional resources/support are available as detailed below:

- **Cancer Research UK (CRUK):** <https://www.cancerresearchuk.org>
- **Myeloma UK:** <https://www.myeloma.org.uk>.
- **Myeloma UK Info Line:** 0800 980 3332
- **Blood Cancer UK:** <https://bloodcancer.org.uk>.
- **Blood Cancer UK Support Line:** 0808 2080 888

These results are about the Randomisation 2 (consolidation and maintenance) part of the trial. We will include results from the Randomisation 1 part of the trial when they are available.

This trial shows that consolidation treatment with thalidomide, dexamethasone and ixazomib followed by maintenance treatment with ixazomib **worked better** after a second stem cell transplant. This is when it was compared with the current standard of care, which is no further treatment.

These results are based on the 206 people who went through Randomisation 2. Of these, 103 people had consolidation and maintenance treatment and 103 people had regular follow up with no further treatment.

We looked at the average time it took from the point at which the person was randomised into the trial until the myeloma came back. On average it took 21 months for people in the consolidation and maintenance group and 13 months for people in the no further treatment group.

These results are based on the data we have up to April 2023 for people who went through Randomisation 2. We do not know yet if there are any differences between these 2 groups in terms of how long people are living or what their quality of life was like. We will continue to publish our results as they become available.

The scientific article detailing the trial results was published in the Lancet Haematology journal and can be accessed via the link below:

<https://pubmed.ncbi.nlm.nih.gov/39250926/>

We would like to thank all participants, patient representatives and recruiting NHS hospitals for making this research possible.

Myeloma XII Team